Aganitha accelerates drug discovery and development by applying the power of Genomics, AI, Cloud and Devops. Discovery and development of drugs today is dramatically different from even a decade ago. Available innovation paths have rapidly expanded from small molecules, natural and recombinant biologicals to targeted cell, gene and advanced therapies that use viral and non-viral nano technologies as delivery vectors. Mechanisms of action are increasingly diverse with explosive innovation driving them. Most of the research has also progressed from single drugs to platform solutions.A notable change in BioPharma has been the emergence of cross-disciplinary research and development. Chemistry, biology, and most medical applications are being transformed by rapid progress in informatics, data and AI/machine learning. The current global pandemic of COVID only highlights a problem known for a few years: there’s a large unmet need for rapid development and manufacture of medicines (preventive & cures) for new as well as previously known diseases.At Aganitha, we partner with global bio-pharma to complement the traditional lab based approaches with in-silico approaches to research and development. We develop and deploy AI, data and cloud powered solutions that efficiently tackle the complexity, scale and richness of modern biopharma R&D domains. We adopt multi-disciplinary approaches blending and translating the latest knowledge in Biology, Chemistry, Computing and BioPharma Business.

As global head of delivery for Transformation Service offerings which included all aspects of Digital solutions and Analytics, I've had the responsibility of managing the fastest growing Application Services unit for more than a decade.In that time, we grew from modest beginnings of a just-acquired start-up unit at $2M per annum run rate to $750M per annum global unit by the time I handed over the reins to a highly talented next-gen leadership team.I take pride in the fact that the unit continues to be the fastest growing and most admired unit after my exit as well.

Savera was a VC-funded startup founded by a highly talented team specialising in big data systems at Bell labs and other leading research labs at the time.I've had the good fortune of being mentored by the best of technical leadership at Savera, in the engineering of high-performance transaction processing and analytical systems.

Responsible for modelling, design and optimisation of fusing sub-system in high-end digital color copiers and printer systems.